Non-invasive distal femoral expandable endoprosthesis for limb-salvage surgery in paediatric tumours.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 4. J Bone Oncol. 2021 Oct 11;31:100397. doi: 10.1016/j.jbo.2021.100397. eCollection 2021 Dec. Frequency and reason for reoperation following non-invasive expandable endoprostheses: A systematic review. Lex JR(1)(2), Adlan A(1), Tsoi K(2)(3), Evans S(1), Stevenson JD(1)(4). Author information: (1)The Royal Orthopaedic Hospital, Oncology Department, Birmingham, West Midlands B31 2AP, UK. (2)Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Canada. (3)University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Canada. (4)Aston University Medical School, Aston University, Birmingham, UK. BACKGROUND: Non-invasive expandable endoprostheses (NIEPR) utilize an external electromagnetic field to drive an innate mechanical gearbox. This lengthens the extremity following oncological resections in children with a predicted limb length discrepancy (LLD), facilitating limb-salvage. This review was conducted to assess NIEPR implant survival rates and identify modes of implant failure unique to these prostheses. METHODS: Medline, EMBASE and the Cochrane Library databases were searched for all manuscripts evaluating implant survival of NIEPRs implanted into skeletally immature patients following resection of extremity sarcomas. Minimum follow-up of 12 months or implant failure was required for inclusion. Failures were classified using the latest ISOLS classification and exact implant-specific failure modality was also identified. RESULTS: 19 studies met inclusion criteria. Mean age was 10.0 years (7.7 - 11.4 years). The most common locations for NIEPR implantation were the distal femur (343, 76.7%) and proximal tibia (53, 119%). Mean follow-up was 65.3 months (19.4 - 163 months). The overall implant revision rate was 46.2% (0 - 100%); implant specific revisions included maximal prosthesis lengthening with persistent LLD (10.4%), failed extension mechanism (6.1%), implant fracture (7.7%), hinge fracture (1.4%) and bushing wear (0.9%). Persistent clinically significant (>20 mm) LLD at final follow-up was present in 19.2% (0 - 50%) of patients. The mean MSTS score was 85.1% (66.7-96.3%) at final follow-up. CONCLUSION: Implant-related failures are the most common reason for NIEPR revision. Implant reliability appears to be improved with current designs. A sub-classification to the current classification system based on implant-specific failures for NIEPRs is proposed. © 2021 Published by Elsevier GmbH. DOI: 10.1016/j.jbo.2021.100397 PMCID: PMC8529098